Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.53 |
| ▸ | ITGAV | P06756 | 7/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5024074 | 0.77 | ITGB3 (0.48) | ITGB3ITGAVALDH1A1 | |
| SCHEMBL5023988 | 0.74 | ITGB3 (0.47) | ITGB3ITGAVSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL6426207 | 0.74 | ITGB3 (0.71) | ITGB3ITGAV | |
| SCHEMBL5879588 | 0.69 | MMP2 (0.62) | ITGB3ITGAVMMP2MMP13MMP9 | |
| SCHEMBL5029896 | 0.66 | ITGB3 (0.79) | ITGB3ITGAV | |
| SCHEMBL5028375 | 0.66 | ITGB3 (0.46) | ITGB3ITGAV | |
| SCHEMBL5879901 | 0.65 | ITGB3 (0.73) | ITGB3ITGAVMMP2MMP13MMP9 | |
| SCHEMBL6444182 | 0.65 | ITGB3 (0.56) | ITGB3ITGAVTP53KDM4EALDH1A1 | |
| SCHEMBL5030065 | 0.65 | — | — | |
| SCHEMBL6440551 | 0.64 | BCHE (0.61) | ITGB3ITGAVMMP2MMP13MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ABBOTT GMBH & CO. KG (DE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ITGB3, ITGAV, ITGA2B | ITGB3 1/4885ITGAV 2/4885MMP2 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.